Skip to Content
Heart failure is a condition in which the heart does not pump enough blood to meet the needs of the body’s tissues. Heart failure can develop slowly over time as the result of other conditions (such as high blood pressure and coronary artery disease) that weaken the heart. It can also occur suddenly as the result of damage to the heart muscle.
Common signs and symptoms of heart failure include:
Treatment for heart failure depends on its severity. All patients need dietary salt restriction and other lifestyle adjustments, medication, and monitoring. Patients with severe heart failure may need implanted devices (such as pacemakers, implantable cardiac defibrillators, or devices that help the heart pump blood) or surgery, including heart transplantation.
Doctors usually treat heart failure, and the underlying conditions that cause it, with a combination of medications. These medications include:
In some cases, doctors may also prescribe other drugs such as:
Other medications that may be helpful include:
Decision Making in Advanced Heart Failure
For patients with advanced heart failure, symptom relief, quality of life, and personal values are as important to consider as survival, advises the American Heart Association (AHA). The AHA notes that while technology has increased the treatment options for advanced heart failure, “doing everything is not always the right thing.” AHA guidelines emphasize a patient-centered approach to treatment and the importance of patients discussing with their doctors their preferences, expectations, and goals.
Heart failure is a condition in which the heart does not pump enough blood to meet the needs of the body’s tissues. To understand what occurs in heart failure, it helps to understand the anatomy of the heart and how it works.
The heart is composed of two independent pumping systems, one on the right side, and the other on the left. Each has two chambers, an atrium and a ventricle. The ventricles are the major pumps in the heart.
The Right Side of the Heart. The right system receives blood from the veins of the whole body. This is "used" blood, which is poor in oxygen and rich in carbon dioxide. In the right side of the heart:
The Left Side of the Heart. The left system receives blood from the lungs. This blood is now rich in oxygen. In the left side of the heart:
The Valves. Valves are muscular flaps that open and close so blood will flow in the right direction. There are four valves in the heart:
The Heart's Electrical System. Heartbeats are triggered and regulated by the conducting system, a network of specialized muscle cells that form a type of electrical system in the heart muscles. These cells are connected by channels that pass chemically-triggered electrical impulses.
Heart failure is a process, not a disease. The heart doesn't "fail" in the sense of ceasing to beat (as occurs during cardiac arrest). Rather, it weakens, usually over the course of months or years, so that it is unable to pump out all the blood that enters its chambers. As a result, fluids build up in the lungs and tissues, causing congestion. This is why heart failure is also sometimes referred to as "congestive heart failure."
Ways the Heart Can Fail. Heart failure can occur in several ways:
Heart failure’s specific effects on the body depend on whether it occurs on the left or right sides of the heart. Over time, in either form of heart failure, the organs in the body do not receive enough oxygen and nutrients, and the body's wastes are removed slowly. Eventually, vital systems break down.
Failure on the Left Side (Left-Ventricular Heart Failure). Failure on the left side of the heart is more common than failure on the right side. The failure can be a result of abnormal systolic (contraction) or diastolic (relaxation) action:
Ejection Fraction. To help determine the severity of left-sided heart failure, doctors use an ejection fraction (EF) calculation, also called a left-ventricular ejection fraction (LVEF). This is the percentage of the blood pumped out from the left ventricle during each heartbeat. An ejection fraction of 50 - 75% is considered normal. Patients with left-ventricular heart failure are classified as either having a preserved ejection fraction (greater than 50%) or a reduced ejection fraction (less than 50%).
Patients with preserved LVEF heart failure are more likely to be female and older, and have a history of high blood pressure and atrial fibrillation (a disturbance in heart rhythm).
Failure on the Right Side (Right-Ventricular Heart Failure). Failure on the right side of the heart is most often a result of failure on the left. Because the right ventricle receives blood from the veins, failure here causes the blood to back up. As a result, the veins surrounding the heart fill up with blood and fluid. This fluid is pushed out into the body’s tissues and causes swelling in the feet, ankles, legs, and abdomen. Pulmonary hypertension (increase in pressure in the lung's pulmonary artery) and lung disease may also cause right-sided heart failure.
Heart failure has many causes and can evolve in different ways.
In all cases, the weaker pumping action of the heart means that less blood is sent to the kidneys. The kidneys respond by retaining salt and water. This in turn increases edema (fluid buildup) in the body, which causes widespread damage.
Uncontrolled high blood pressure (hypertension) is a major cause of heart failure even in the absence of a heart attack. In fact, about 75% of cases of heart failure start with hypertension. It generally develops as follows:
Coronary artery disease is the end result of a process called atherosclerosis (commonly called "hardening of the arteries"). It is the most common cause of heart attack and involves the build-up of cholesterol in the arteries, with inflammation and injury in the cells of the blood vessels. The arteries narrow and become brittle. Heart failure in such cases most often results from a pumping defect in the left side of the heart.
People often survive heart attacks, but many eventually develop heart failure from the damage the attack does to the heart muscles.
The valves of the heart control the flow of blood leaving and entering the heart. Abnormalities can cause blood to back up or leak back into the heart.
In the past, rheumatic fever, which scars the heart valves and prevents them from functioning properly, was a major cause of death from heart failure. Fortunately, antibiotics and other advances have now made this disease a minor cause of heart failure in industrialized nations. Birth defects may also cause abnormal valvular development. Although more children born with heart defects are now living to adulthood, they still face a higher than average risk for heart failure as they age.
Cardiomyopathy is a disorder that damages the heart muscles and leads to heart failure. There are several different types. Injury to the heart muscles may cause the heart muscles to thin out (dilate) or become too thick (become hypertrophic). In either case, the heart doesn't pump correctly. Viral myocarditis is a rare viral infection that involves the heart muscle and can produce either temporary or permanent heart muscle damage.
Dilated Cardiomyopathy. Dilated cardiomyopathy involves an enlarged heart ventricle. The muscles thin out, reducing the pumping action, usually on the left side. Although this condition is associated with genetic factors, the direct cause is often not known. (This is called idiopathic dilated cardiomyopathy.) In other cases, viral infections, alcoholism, and high blood pressure may increase the risk for this condition.
Hypertrophic Cardiomyopathy. In hypertrophic cardiomyopathy, the heart muscles become thick and have difficulty contracting. Hypertrophic cardiomyopathy may be due to a genetic defect that causes a loss of power in heart muscle cells and, subsequently, lower pumping strength. To compensate for this power loss, the heart muscle cells grow. This condition, rare in the general population, is often the cause of sudden death in young athletes.
Restrictive Cardiomyopathy. Restrictive cardiomyopathy refers to a group of disorders in which the heart chambers are unable to properly fill with blood because of stiffness in the heart. The heart is of normal size or only slightly enlarged. However, it cannot relax normally during the time between heartbeats when the blood returns from the body to the heart (diastole). The most common causes of restrictive cardiomyopathy are amyloidosis and scarring of the heart from an unknown cause (idiopathic myocardial fibrosis). It often occurs after heart transplant.
Chronic obstructive pulmonary disease (severe chronic bronchitis or emphysema) and other major lung diseases are risk factors for right-sided heart failure. Pulmonary hypertension is increased pressure in the pulmonary arteries that carry blood from the right side of the heart to the lungs. The increased pressure makes the heart work harder to pump blood, which can cause heart failure. .
An overactive thyroid (hyperthyroidism) or underactive thyroid (hypothyroidism) can have severe effects on the heart and increase the risk for heart failure.
Coronary artery disease, heart attack, and high blood pressure are the main causes and risk factors of heart failure. Other diseases that damage or weaken the heart muscle or heart valves can also cause heart failure. Heart failure is most common in people over age 65, African-Americans, and women.
Heart failure risk increases with advancing age. Heart failure is the most common reason for hospitalization in people age 65 years and older.
Men are at higher risk for heart failure than women. However, women are more likely than men to develop diastolic heart failure (a failure of the heart muscle to relax normally), which is often a precursor to systolic heart failure (impaired ability to pump blood).
African-Americans are more likely than Caucasians to develop heart failure before age 50 and die from the condition.
People with a family history of cardiomyopathies (diseases that damage the heart muscle) are at increased risk of developing heart failure. Researchers are investigating specific genetic variants that increase heart failure risk.
People with diabetes are at high risk for heart failure, particularly if they also have coronary artery disease and high blood pressure. Some types of diabetes medications, such as rosiglitazone (Avandia) and pioglitazone (Actos), may cause or worsen heart failure. Chronic kidney disease caused by diabetes also increases heart failure risk.
Obesity is associated with both high blood pressure and type 2 diabetes, conditions that place people at risk for heart failure. Evidence strongly suggests that obesity itself is a major risk factor for heart failure, particularly in women.
Smoking, sedentary lifestyle, and alcohol and drug abuse can increase the risk for developing heart failure.
Certain drugs can potentially damage the heart and increase the risk for heart failure. Long-term use of high-dose anabolic steroids (male hormones used to build muscle mass) increases the risk for heart failure. The cancer drug imatinib (Gleevec) has been associated with heart failure. Other chemotherapy drugs, such as doxorubicin, can increase the risk for developing heart failure years after cancer treatment. (Cancer radiation therapy to the chest can also damage the heart muscle.)
The complications caused by heart failure influence a patient’s chance for survival. Although heart failure produces very high mortality rates, treatment advances are improving survival rates.
Cardiac Cachexia. If patients with heart failure are overweight to begin with, their condition tends to be more severe. Once heart failure develops, an important indicator of a worsening condition is the occurrence of cardiac cachexia, which is unintentional rapid weight loss (a loss of at least 7.5% of normal weight within 6 months).
Impaired Kidney Function. Heart failure weakens the heart’s ability to pump blood. This can affect other parts of the body including the kidneys (which in turn can lead to fluid build-up). Decreased kidney function is common in patients with heart failure, both as a complication of heart failure and other diseases associated with heart failure (such as diabetes). Studies suggest that, in patients with heart failure, impaired kidney function increases the risks for heart complications, including hospitalization and death.
Congestion (Fluid Buildup). In left-sided heart failure, fluid builds up first in the lungs, a condition called pulmonary edema. Later, as right-sided heart failure develops, fluid builds up in the legs, feet, and abdomen. Fluid buildup is treated with lifestyle measures, such as reducing salt in the diet, as well as drugs, such as diuretics.
Arrhythmias (Irregular Beatings of the Heart). There are several types of arrhythmias:
Angina and Heart Attacks. While coronary artery disease is a major cause of heart failure, patients with heart failure are at continued risk for angina and heart attacks. Special care should be taken with sudden and strenuous exertion, particularly snow shoveling, during colder months.
Many symptoms of heart failure result from the congestion that develops as fluid backs up into the lungs and leaks into the tissues. Other symptoms result from inadequate delivery of oxygen-rich blood to the body's tissues. Since heart failure can progress rapidly, it is essential to consult a doctor immediately if any of the following symptoms are detected:
Fatigue. Patients may feel unusually tired.
Shortness of Breath (Dyspnea). Symptoms and types of dyspnea include:
Fluid Retention (Edema) and Weight Gain. Heart failure can cause foot, ankle, leg or abdominal swelling. In rare cases, swelling can occur in the veins of the neck. Fluid retention can cause sudden weight gain and frequent urination.
Wheezing or Cough. Heart failure can cause asthma-like wheezing, or a dry hacking cough that occurs a few hours after lying down but then stops after sitting up.
Loss of Muscle Mass. Over time, patients may lose muscle weight due to low cardiac output and a significant reduction in physical activity.
Gastrointestinal Symptoms. Problems include loss of appetite or a sense of feeling full after eating small amounts. Patients may also have abdominal pain.
Pulmonary Edema. When fluid in the lungs builds up, it is called pulmonary edema, which produces severe symptoms. that may develop suddenly or gradually build up over a matter of days:
Abnormal Heart Rhythms. Heart failure can cause episodes of abnormally fast or slow heart rate.
Central Sleep Apnea. This sleep disorder results when the brain fails to signal the muscles to breathe during sleep. It occurs in up to half of people with heart failure. Sleep apnea causes disordered breathing at night. If heart failure progresses, the apnea may be so acute that a person, unable to breathe, may awaken from sleep in panic.
Doctors can often make a preliminary diagnosis of heart failure by medical history and careful physical examination.
A thorough medical history may identify risks for heart failure that include:
The following physical signs, along with medical history, strongly suggest heart failure:
Both blood and urine tests are used to check for problems with the liver and kidneys and to detect signs of diabetes. Lab tests can measure:
An electrocardiogram (ECG) is a test that measures and records the electrical activity of the heart. It is also called an EKG. An electrocardiogram cannot diagnose heart failure, but it may indicate underlying heart problems. The test is simple and painless to perform. It may be used to diagnose:
A completely normal ECG means that heart failure is unlikely.
The best diagnostic test for heart failure is echocardiography. Echocardiography is a noninvasive test that uses ultrasound to image the heart as it is beating. Cardiac ultrasounds provide the following information:
Doctors use information from the echocardiogram for calculating the ejection fraction (how much blood is pumped out during each heartbeat), which is important for determining the severity of heart failure. Stress echocardiography may be needed if coronary artery disease is suspected.
Doctors may recommend angiography if they suspect that blockage of the coronary arteries is contributing to heart failure. This procedure is invasive.
Radionuclide Ventriculography. Radionuclide ventriculography is an imaging technique that uses a tiny amount of radioactive material (called a trace element). It is very sensitive in revealing heart enlargement or evidence of fluid accumulation around the heart and lungs. It may be done at the same time as coronary artery angiography. It can help diagnose or exclude the presence of coronary artery disease and also demonstrate how the heart works during exercise.
Chest x-rays can show whether the heart is enlarged. Computed tomography (CT) and magnetic resonance imaging (MRI) may also be used to evaluate the heart valves and arteries.
The exercise stress test measures heart rate, blood pressure, electrocardiographic changes, and oxygen consumption while a patient is performing physically, usually walking on a treadmill. It can help determine heart failure symptoms. Doctors also use exercise tests to evaluate long-term outlook and the effects of particular treatments. A stress test may be done using echocardiography or may be done as a nuclear stress test (myocardial perfusion imaging).
Heart failure is classified into four stages (Stage A through Stage D) that reflect the development and progression of the condition. Treatment depends on the stage of heart failure.
Stage A is not technically heart failure, but indicates that a patient is at high risk for developing it. In Stage B, the patient has had damage to the heart (for example, from a heart attack) but does not yet have symptoms of heart failure. In Stage C, heart failure symptoms manifest.
Stage D is advanced heart failure accompanied by symptoms that may be difficult to manage with standard drug treatments and may require more technologically complex care (defibrillators, mechanical pumps, heart transplantation). The American Heart Association emphasizes the importance of a patient-centered approach to treatment decisions. Patients with advanced heart failure should have ongoing honest discussions with their health care providers concerning their personal preferences and quality of life goals.
Stage A. In Stage A, patients are at high risk for heart failure but do not show any symptoms or have structural damage of the heart. The first step in managing or preventing heart failure is to treat the primary conditions that cause or complicate heart failure. Risk factors include high blood pressure, heart diseases, diabetes, obesity, metabolic syndrome, and previous use of medications that damage the heart (such as some chemotherapy).
Important risk factors to manage include:
Stage B. Patients have a structural heart abnormality seen on echocardiogram or other imaging tests but no symptoms of heart failure. Abnormalities include left ventricular hypertrophy and low ejection fraction, asymptomatic valvular heart disease, and a previous heart attack. In addition to the treatment guidelines for Stage A, the following types of drugs and devices may be recommended for some patients:
Stage C. Patients have a structural abnormality and current or previous symptoms of heart failure, including shortness of breath, fatigue, and difficulty exercising. Treatment includes those for Stage A and B plus:
Stage D. Patients have end-stage symptoms that do not respond to standard treatments. Treatment focuses not only on survival but on symptom relief and quality of life issues. Treatment includes appropriate measures used for Stages A, B, and C plus:
Whenever heart failure worsens, whether quickly or chronically over time, various factors must be considered as the cause:
Many different medications are used in the treatment of heart failure. They include:
Angiotensin-converting enzyme (ACE) inhibitors are among the most important drugs for treating patients with heart failure. ACE inhibitors open blood vessels and decrease the workload of the heart. They are used to treat high blood pressure but can also help improve heart and lung muscle function. ACE inhibitors are particularly important for patients with diabetes, because they also help slow progression of kidney disease.
Brands and Indications. ACE inhibitors are used to treat Stage A high-risk conditions such as high blood pressure, heart disease, and diabetic nerve disorders (neuropathy). They are also used to treat Stage B patients who have had a heart attack or who have left ventricular systolic disorder, and Stage C patients with heart failure. Specific brands of ACE inhibitors include:
Side Effects of ACE Inhibitors:
ARBs, also known as angiotensin II receptor antagonists, are similar to ACE inhibitors in their ability to open blood vessels and lower blood pressure. They may have fewer or less-severe side effects than ACE inhibitors, especially coughing, and are sometimes prescribed as an alternative to ACE inhibitors. Some patients with heart failure take an ACE inhibitor along with an ARB.
Brands and Indications. ARBs are used to treat Stage A high-risk conditions such as high blood pressure and diabetic nerve disorders (neuropathy). They are also used to treat Stage B patients who have had a heart attack or who have left ventricular systolic disorder, and Stage C patients with heart failure. Specific brands include:
Common Side Effects
Beta blockers are almost always used in combination with other drugs, such as ACE inhibitors and diuretics. They help slow heart rate and lower blood pressure. When used properly, beta blockers can reduce the risk of death or rehospitalization.
Brands and Indications. Beta blockers treat Stage A high blood pressure. They also treat Stage B patients (both those who have had a heart attack and those who have not had a heart attack but who have heart damage). A specialist should monitor patients with heart failure who take beta blockers. The three beta blockers that are best for treating Stage C patients with heart failure are:
Beta Blocker Concerns
Common Side Effects
Check with your doctor about any side effects. Do not stop taking these drugs on your own.
Diuretics cause the kidneys to rid the body of excess salt and water. Fluid retention is a major symptom of heart failure. Aggressive use of diuretics can help eliminate excess body fluids, while reducing hospitalizations and improving exercise capacity. These drugs are also important to help prevent heart failure in patients with high blood pressure. In addition, certain diuretics, notably spironolactone (Aldactone, generic), block aldosterone, a hormone involved in heart failure. This drug class is beneficial for patients with more severe heart failure (Stages C and D).
Diuretics come in many brands and are generally inexpensive. Some need to be taken once a day, some twice a day. Diuretics are usually started at a low dose and gradually increased. Your doctor may advise you to adjust the amount and timing of the diuretic if you notice swelling or weight gain. Diuretics are virtually always used in combination with other drugs, especially ACE inhibitors and beta blockers.
There are three main types of diuretics:
Side Effects. In addition to increased urination, all types of diurectics may cause dry mouth, dehydration, fatigue, muscle cramps, and dizziness and lightheadedness. Diuretics can increase the amount of uric acid in the blood, which can lead to gout. In men, diurectics may produce erectile dysfunction.
Potassium imbalances are an important concern with diuretics:
Aldosterone is a hormone that is critical in controlling the body's balance of salt and water. Excessive levels play important roles in high blood pressure and heart failure. Drugs that block aldosterone are prescribed for some patients with symptomatic heart failure. They reduce death rates for patients with heart failure and coronary artery disease, especially after a heart attack.
Aldosterone blocker brands include spironolactone (Aldactone, generic) and eplerenone (Inspra, generic).
Like loop and thiazide diuretics, aldosterone blockers can cause abnormally high levels of potassium in the blood. Patients should not take potassium supplements at the same time as this drug and may need to avoid foods with high potassium content.
Digitalis is derived from the foxglove plant. It has been used to treat heart disease since the 1700s. Digoxin (Lanoxin, generic) is the most commonly prescribed digitalis preparation. Digoxin decreases heart size and reduces certain heart rhythm disturbances (arrhythmias). Although it was once a mainstay of heart failure treatment, it is now used less often than newer drugs.
Digitalis may be useful for select patients with left-ventricular systolic dysfunction who do not respond to other drugs (diuretics, ACE inhibitors). It may also be used for patients who have atrial fibrillation.
Side Effects and Problems. While digitalis is generally a safe drug, it can have severe adverse side effects. The most serious side effects are arrhythmias. Early signs of toxicity may be irregular heartbeat, nausea and vomiting, stomach pain, fatigue, visual disturbances (such as yellow vision, seeing halos around lights, flickering or flashing of lights), and emotional and mental disturbances.
Many factors increase the chance for side effects.
Digitalis also interacts with many other drugs, including quinidine, amiodarone, verapamil, flecainide, amiloride, and propafenone.
For most patients with mild-to-moderate heart failure, low-dose digoxin may be as effective as higher doses. If side effects are mild, patients should still consider continuing with digitalis if they experience other benefits.
Hydralazine and nitrates are two older drugs that help relax arteries and veins, thereby reducing the heart's workload and allowing more blood to reach the tissues. They are used primarily for patients who are unable to tolerate ACE inhibitors and angiotensin receptor blockers. BiDil is a drug that combines isosorbide dinitrate and hydralazine. BiDil is approved to specifically treat heart failure in African-American patients.
Statins are important drugs used to lower cholesterol and to prevent heart disease leading to heart failure. These drugs include lovastatin (Mevacor, generic), pravastatin (Pravachol, generic), simvastatin (Zocor, generic), fluvastatin (Lescol), atorvastatin (Lipitor, generic), rosuvastatin (Crestor), and pitavastatin (Livalo). Atorvastatin is specifically approved to reduce the risks for hospitalization for heart failure in patients with heart disease.
Anti-platelet and anticoagulant drugs help thin the blood and prevent the formation of blood clots. It is not clear if these drugs are helpful for patients with heart failure who are not at risk for blood clots.
Aspirin. Aspirin is a type of non-steroid anti-inflammatory (NSAID). Aspirin is recommended for protecting patients with heart disease, and can safely be used with ACE inhibitors, particularly when it is taken in lower dosages (75 - 81 mg).
Warfarin (Coumadin, generic). Warfarin is recommended only for patients with heart failure who also have:
Nesiritide (Natrecor). Nesiritide is an intravenous drug that has been used for hospitalized patients with decompensated heart failure. Decompensated heart failure is a life-threatening condition in which heart failure progresses over the course of minutes or a few days, often as the result of a heart attack or sudden and severe heart valve problems. Because nesiritide may cause serious kidney damage and has been linked to an increased risk of death from heart failure, the drug is of limited value.
Erythropoietin. Erythropoietin is used to treat anemia, which is a common complication of heart failure. This drug can increase the risk of blood clots and its exact role or the treatment of anemia in patients with heart failure is not yet decided
Tolvaptan. Tolvaptan (Samsca) is a drug approved for treating hyponatremia (low sodium levels) associated with heart failure and other conditions.
Levosimendan. Levosimendan is an experimental drug that is being investigated as a treatment for severely ill patients with heart failure. It belongs to a new class of drugs called calcium sensitizers that may help improve heart contractions and blood flow. The drug appears to reduce levels of BNP (brain natriuretic peptide), a chemical marker for heart failure severity.
Revascularization surgery helps to restore blood flow to heart affected by coronary artery disease. It can treat blocked arteries in patients with coronary artery disease and may help select patients with heart failure. Surgery types include coronary artery bypass graft (CABG) and angioplasty (also called percutaneous coronary intervention [PCI]). CABG is a traditional type of open heart surgery. Angioplasty is a less-invasive procedure that uses a catheter to inflate a balloon inside the artery. A metal stent may also be inserted during an angioplasty procedure.
Pacemakers, also called pacers, help regulate the heart’s beating action, especially when the heart beats too slowly. Biventricular pacers (BVPs) are a special type of pacemaker used for patients with heart failure. Because BVPs help the heart’s left and right chambers beat together, this treatment is called cardiac resynchronization therapy (CST).
BVPs are recommended for patients with moderate-to-severe heart failure that is not controlled with medication therapy and who have evidence of left-bundle branch block on their EKG. Left-bundle branch block is a condition in which the electrical impulses in the heart do not follow their normal pattern, causing the heart to pump inefficiently.
Patients with enlarged hearts are at risk for having serious cardiac arrhythmias (abnormal heartbeats) that are associated with sudden death. Implantable cardioverter defibrillators (ICDs) can quickly detect life-threatening arrhythmias. The ICD is designed to convert any abnormal heart rhythm back to normal by sending an electrical shock to your heart. This action is called defibrillation. This device can also work as a pacemaker.
Patients with ICDs need to avoid certain types of electronic devices that can disrupt the device. They may also need to avoid certain types of medical and imaging procedures. It is important to talk with your doctor about any questions you have about living with an ICD. Be sure to let your doctor know if you feel anxious or depressed –it’s not uncommon for patients with ICDs to experience these emotions, and psychological support is important for both patients and their families.
In recent years, certain ICD models and biventricular pacemaker-defibrillators have been recalled by the manufacturers because of circuitry flaws. However, doctors stress that the chance of an ICD or pacemaker saving a person’s life far outweigh the possible risks of these devices failing.
Ventricular assist devices are mechanical devices that help improve pumping actions. They are used as a bridge to transplant for patients who are on medications but still have severe symptoms and are waiting for a donor heart. In some cases, they may delay the need for a transplant. Therefore they may be used as short-term (less than 1 week) or longer term support.
Ventricular assist devices include:
The risks and complications involved with many of these devices include bleeding, blood clots, and right-side heart failure. Infections are a particular hazard.
Patients who suffer from severe heart failure and whose symptoms do not improve with drug therapy or mechanical assistance may be candidates for heart transplantation. About 2,000 heart transplant operations are performed in the United States each year, but thousands more patients wait on a list for a donor heart.
The most important factor for heart transplant eligibility is overall health. Chronological age is less important. Most heart transplant candidates are between the ages of 50 - 64 years.
While the risks of this procedure are high, about 85 - 90% of patient survive the first year after receiving a heart transplant, and about 75% survive for 5 years. Survival after 10 years is about 56 percent. In general, the highest risk factors for death 3 or more years after a transplant operation are coronary artery disease and the adverse effects (infection and certain cancers) of immunosuppressive drugs used in the procedure. .
Artificial hearts are implantable devices that serve as replacement for the heart’s failing valves. There are two types of artificial hearts. The SynCardia Total Artificial Heart is used to help sustain patients who are waiting for a heart transplant. Abiocor is a permanent implantable artificial heart. It is available only for patients who are not eligible for a heart transplant and who are not expected to live more than a month without medical treatment. Both of these devices are very expensive, require complex surgery, and only extend survival by a few months. Patients need to have a chest cavity large enough to contain the device, which excludes most women.
Up to half of patients hospitalized for heart failure are back in the hospital within 6 months. Many people return because of lifestyle factors, such as poor diet, failure to comply with medications, and social isolation.
Programs that offer intensive follow-up to ensure that the patient complies with lifestyle changes and medication regimens at home can reduce rehospitalization and improve survival. Patients without available rehabilitation programs should seek support from local and national heart associations and groups. A strong emotional support network is also important.
Patients should weigh themselves each morning and keep a record. Any changes are important:
Sodium (Salt) Restriction. All patients with heart failure should limit their sodium (salt) intake to less than than 2,300 mg a day. (Check with your doctor for exact sodium limits.) Do not add salt to cooking and meals, and avoid foods high in sodium. These salty foods include ham, bacon, hot dogs, lunch meats, prepared snack foods, dry cereal, cheese, canned soups, soy sauce, and condiments. Some patients may need to reduce the amount of water they consume. People with high cholesterol levels or diabetes require additional dietary precautions.
Here are some tips to lower your salt and sodium intake:
People with heart failure used to be discouraged from exercising. Now, doctors think that exercise, when performed under medical supervision, is extremely important for stable patients. Studies have reported that patients with stable conditions who engage in regular moderate exercise (three times a week) have a better quality of life and lower mortality rates than those who do not exercise. However:
Studies report benefits from specific exercises:
Some people with severe heart failure need periods of bed rest. To reduce congestion in the lungs, the patient's upper body should be elevated. For most patients, resting in an armchair is better than lying in bed. Relaxing and contracting leg muscles is important to prevent clots. As the patient improves, a doctor will progressively recommend more activity.
Stress reduction techniques, such as meditation and relaxation response methods, may have direct physical benefits. Anxiety can cause the heart to work harder and beat faster.
Patients with heart failure may seek alternative remedies. Despite various claims, there is no strong evidence to support their effectiveness. Some herbs and dietary supplements can pose specific risks for patients with heart failure:
Generally, manufacturers of herbal remedies and dietary supplements do not need FDA approval to sell their products. Just like a drug, herbs and supplements can affect the body's chemistry, and therefore have the potential to produce side effects that may be harmful. There have been several reported cases of serious and even lethal side effects from herbal products. Always check with your doctor before using any herbal remedies or dietary supplements.
Adabag S, Roukoz H, Anand IS, Moss AJ. Cardiac resynchronization therapy in patients with minimal heart failure: a systematic review and meta-analysis. J Am Coll Cardiol. 2011 Aug 23;58(9):935-41.
Allen LA, Stevenson LW, Grady KL, Goldstein NE, Matlock DD, Arnold RM, et al. Decision Making in Advanced Heart Failure: A Scientific Statement From the American Heart Association. Circulation. 2012 Apr 17;125(15):1928-1952. Epub 2012 Mar 5.
Al-Majed NS, McAlister FA, Bakal JA, Ezekowitz JA. Meta-analysis: cardiac resynchronization therapy for patients with less symptomatic heart failure. Ann Intern Med. 2011 Mar 15;154(6):401-12. Epub 2011 Feb 14.
American Academy of Family Physicians; American Academy of Hospice and Palliative Medicine; American Nurses Association; American Society of Health-System Pharmacists; Heart Rhythm Society; Society of Hospital Medicine, et al. ACCF/AHA/AMA-PCPI 2011 performance measures for adults with heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Performance Measures and the American Medical Association - Physician Consortium for Performance Improvement. J Am Coll Cardiol. 2012 May 15;59(20):1812-32. Epub 2012 Apr 23.
Dunbar SB, Dougherty CM, Sears SF, Carroll DL, Goldstein NE, Mark DB, et al. Educational and psychological interventions to improve outcomes for recipients of implantable cardioverter defibrillators and their families: a scientific statement from the American Heart Association. Circulation. 2012 Oct 23;126(17):2146-72. Epub 2012 Sep 24.
Epstein AE, DiMarco JP, Ellenbogen KA, Estes NA 3rd, Freedman RA, Gettes LS, et al. 2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2013 Jan 22;61(3):e6-75. Epub 2012 Dec 19.
Gissi-HF Investigators, Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, et al. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008 Oct 4;372(9645):1223-30. Epub 2008 Aug 29.
Greenberg B and Kahn AM. Clinical assessment of heart failure. In: Bonow RO, Mann DL, Zipes DP, Libby P, eds. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. 9th ed. Saunders; 2011:chap 26.
Haykowsky MJ, Liang Y, Pechter D, Jones LW, McAlister FA, Clark AM. A meta-analysis of the effect of exercise training on left ventricular remodeling in heart failure patients: the benefit depends on the type of training performed. J Am Coll Cardiol. 2007 Jun 19;49(24):2329-36. Epub 2007 Jun 4.
Heart Failure Society of America, Lindenfeld J, Albert NM, Boehmer JP, Collins SP, Ezekowitz JA, et al. HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail. 2010 Jun;16(6):e1-194.
Hildebrandt P. Systolic and nonsystolic heart failure: equally serious threats. JAMA. 2006 Nov 8;296(18):2259-60.
Mann DL. Pathophysiology of heart failure. In: Bonow RO, Mann DL, Zipes DP, Libby P, eds. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. 9th ed. Saunders; 2011:chap 25.
O'Connor CM, Starling RC, Hernandez AF, Armstrong PW, Dickstein K, Hasselblad V, et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med. 2011 Jul 7;365(1):32-43.
Peura JL, Colvin-Adams M, Francis GS, Grady KL, Hoffman TM, Jessup M, et al. Recommendations for the use of mechanical circulatory support: device strategies and patient selection: a scientific statement from the American Heart Association. Circulation. 2012 Nov 27;126(22):2648-67. Epub 2012 Oct 29.
Risk and Prevention Study Collaborative Group, Roncaglioni MC, Tombesi M, Avanzini F, Barlera S, Caimi V, et al. n-3 fatty acids in patients with multiple cardiovascular risk factors. N Engl J Med. 2013 May 9;368(19):1800-8.
Schocken DD, Benjamin EJ, Fonarow GC, Krumholz HM, Levy D, Mensah GA, et al. Prevention of heart failure: a scientific statement from the American Heart Association Councils on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group. Circulation. 2008 May 13;117(19):2544-65. Epub 2008 Apr 7.
Tachjian A, Maria V, Jahangir A. Use of herbal products and potential interactions in patients with cardiovascular diseases. J Am Coll Cardiol. 2010 Feb 9;55(6):515-25.